Celldex Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing mast cell biology and developing therapeutic antibodies. The company's proprietary pipeline targets severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. Celldex's lead program is barzolvolimab (CDX-0159), a humanized monoclonal antibody that binds with high specificity to the KIT receptor, potently inhibiting its activity to deplete and control mast cells. Additionally, the company is expanding its pipeline with CDX-622, a novel bispecific antibody targeting both soluble stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead candidate barzolvolimab (a humanized monoclonal antibody targeting the KIT receptor) through Phase 3 registrational trials for chronic spontaneous urticaria (CSU) and chronic inducible urticarias (ColdU and SD), alongside Phase 2 trials in prurigo nodularis and atopic dermatitis.
Expected impact: Establishment of a first-in-class and best-in-disease immunology franchise targeting mast cell-mediated diseases.
Developing and expanding the company's bispecific antibody pipeline, led by CDX-622, which targets both stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP) to address non-overlapping mast cell populations in inflammatory diseases.
Expected impact: Diversification of the clinical pipeline beyond the lead barzolvolimab program.